Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 51

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 51
---
 127,551 shares of its common stock, par value $0.0001 per share
(the “Common Stock”) or common stock equivalents in lieu thereof (the Company sold 15,000 shares of its common stock and 112,551
pre-funded warrants); and (ii) common warrants to purchase up to 127,551 shares of common stock (the “Warrants”), at a combined
public offering price of $39.20 per share and Warrant. In connection with the Offering, on February 5, 2025, the Company entered into
a securities purchase agreement (the “SPA”) with the investors. The SPA contains customary representations, warranties and
agreements of the Company and each investor and customary indemnification rights and obligations of the parties. In connection with this
offering, the Company received net proceeds of approximately $4.2 million, which is net of offering costs and fees of $839,004. During
the three months ended March 31, 2025, 15,000 shares of common stock were purchased upon the closing of the Offering and 91,214 shares
were issued in connection with the exercise of pre-funded warrants, totaling 106,214 shares of its common stock issued of the aggregate
amount of 127,551 Common Stock shares sold. During the three months ended June 30, 2025, 10,550 shares were issued in connection with
the exercise of pre-funded warrants. At June 30, 2025, 10,787 pre-funded warrants remain exercisable.

The Warrants have an exercise price of $39.20 per share, are immediately exercisable upon stockholder approval and have a term of exercise equal to five years following the initial exercise date. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price.

In connection with the Offering, on February 5, 2025, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Alliance Global Partners (“A.G.P.”), as the exclusive placement agent in connection with the Offering (the “Placement Agent”). Pursuant to a side letter between the Placement Agent and JonesTrading Institutional Services LLC (“Jones”), dated February 3, 2025, Jones agreed to be a financial advisor for the Offering. In connection with the services provided by Jones, the Placement Agent and Jones agreed that